| HOME >> BIOLOGY >> TECHNOLOGY |
(8) Gralnick HR, Vail M, McKeown LP et al. Activated platelets in
paroxysmal nocturnal haemoglobinuria. Br J Haematol. 1995;91:697-702.
(9) Audebert HJ, Planck J, Eisenburg M, Schrezenmeier H, Haberl RL.
Cerebral ischemic infarction in paroxysmal nocturnal hemoglobinuria
report of 2 cases and updated review of 7 previously published
patients. J Neurol. 2005;252:1379-1386.
(10) Hall C, Richards S, Hillmen P. Primary prophylaxis with warfarin
prevents thrombosis in paroxysmal nocturnal haemoglobinuria (PNH).
Blood. 2003;102:3587-3591.
(11) Rosse WF, Nishimura J. Clinical manifestations of paroxysmal
nocturnal hemoglobinuria: present state and future problems. Int J
Hematol. 2003;77:113-120.
(12) Luzzatto L, Gianfaldoni G. Recent advances in biological and clinical
aspects of paroxysmal nocturnal hemoglobinuria. Int J Hematol.
2006;84:104-112.
(13) Hill A, Platts PJ, Smith A et al. The incidence and prevalence of
paroxysmal nocturnal hemoglobinuria (PNH) and survival of patients in
Yorkshire [abstract]. Blood. 2006;108(11):290a. Abstract 985.
(14) Johnson RJ, Hillmen P. Paroxysmal nocturnal hemoglobinemia: Nature's
gene therapy? J Clin Path: Mol Pathol. 2002;55:145-152.
(15) Wang, et al. Clinical significance of a minor population of
paroxysmal nocturnal hemoglobinuria-type cells in bone marrow failure
syndrome. Blood 2002;100:3897-3902.
(16) Iwanga, et al. Paroxysmal nocturnal haemoglobinuria clones in
patients with myelodysplastic syndromes. Brit J Haem. 1998;
102:465-474.
(17) Maciejewski, et al. Relationship between bone marrow failure
syndromes and the presence of glycophosphatidyl inositol-anchored
protein-deficient clones. Brit J Haem. 2001;115:1015
'/>"/>
SOURCE Alexion Pharmaceuticals, Inc.![]() Copyright©2007 PR Newswire. |